Download PDF
Exp Clin Endocrinol Diabetes 2014; 122(05): 268-272
DOI: 10.1055/s-0034-1372624
Article
© J. A. Barth Verlag in Georg Thieme Verlag KG Stuttgart · New York

Correlation among the BRAF Gene Mutation Status, Clinicopathological Features of Primary Tumour, and Lymph Node Metastasizing of Papillary Thyroid Carcinoma

J. Lukas   *
1   Department of Otolaryngology – Head and Neck Surgery, Na Homolce Hospital, Prague, Czech Republic
2   Department of Otolaryngology, Faculty of Medicine, Charles University, Pilsen, Czech Republic
,
J. Drabek   *
3   Laboratory of Experimental Medicine, the Institute of Molecular and ­Translational Medicine of the Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
,
B. Dudesek
4   Department of Surgery, Atlas Hospital, Zlín, Czech Republic
,
P. Vazan
5   Biopsy and Cytology Laboratory of J.A.Baťa, Zlín, Czech Republic
,
J. Stranska
3   Laboratory of Experimental Medicine, the Institute of Molecular and ­Translational Medicine of the Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
,
S. Jancik
3   Laboratory of Experimental Medicine, the Institute of Molecular and ­Translational Medicine of the Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic
,
M. Mackova
6   Department of Nuclear Medicine and Endocrinology, 2nd Medical Faculty, Charles University, Prague, Czech Republic
,
M. Syrucek
7   Department of Pathology, Na Homolce Hospital, Prague, Czech Republic
,
D. Lukas
8   Surgery Clinics, 3rd Medical Faculty, Charles University and Faculty Hospital Královské Vinohrady, Prague, Czech Republic
,
J. Duskova
9   Institute of Pathology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
,
P. Dundr
9   Institute of Pathology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
,
B. Hintnausova
10   Department of Endocrinology, Na Homolce Hospital, Prague, Czech ­Republic
,
J. Jiskra
11   The 3rd Department of Medicine – Department of Endocrinology and ­Metabolism 1st Faculty of Medicine, Charles University in Prague and ­General University Hospital in Prague, Czech Republic
› Author Affiliations
Further Information

Publication History

received 15 December 2013
first decision 11 February 2014

accepted 25 March 2014

Publication Date:
16 May 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Background: Papillary thyroid carcinoma (PTC) is the most common malignant thyroid tumour. A common mutation of papillary thyroid carcinoma (PTC) is the somatic mutation of the BRAF V600E gene.

Aim: The aim was to 1) determine the association of lymph node metastases of PTC with the BRAF gene mutation of primary tumour; 2) evaluate association of the BRAF mutation in the ­primary tumour with clinicopathological para­meters; 3) examine the extent of genetic heterogeneity by monitoring the BRAF mutation in multicentric tumours.

Subjects and methods: Retrospective analysis of the BRAF V600E mutation in PTC and PTC neck lymph node metastases in 156 patients operated from 2003 to 2012 in Prague and Zlín, the Czech Republic, using a qPCR assay. The results were correlated with clinicopathological factors.

Results: DNA was successfully extracted from 137 samples. The BRAF V600E mutation was detected in 78 cases (56.9%). The patients with BRAF p.Val600Glu mutation of primary tumour had only non-significantly higher risk of cervical lymph node metastases [OR=2.39 (95%) CI 1.00–5.75, p=0.052]. In the classic papillary variant, the BRAF V600E mutation was found significantly more often than in other PTC subtypes (p=0.022). We did not confirm any significant association between the BRAF V600E mutation and other clinicopathological findings.

Conclusion: Except for the higher prevalence in papillary variant of PTC, BRAF p.Val600Glu mutation was not associated with other prognostic clinicopathological factors of PTC. BRAF mutation cannot be regarded as a reliable marker of node metastases in patients with PTC.

Key words

papillary carcinoma - BRAFV600E mutation - clinical and pathological parameters - neck node metastases

* Both authors contributed equally to this work.


 

  • References

  • 1 Hundahl SA, Fleming ID, Fremgen AM et al. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [see comments]. Cancer 1998; 83: 2638-2648
    CrossrefPubMedGoogle Scholar
  • 2 Sipos JA, Mazzaferri EL. Thyroid cancer epidemiology and prognostic variables. Clin Oncol (R Coll Radiol) 2010; 22: 395-404
    CrossrefPubMedGoogle Scholar
  • 3 Becker HD, Hohenberger W, Junginger T et al. Chirurgicka onkologie 2005; 1: 1-880
    PubMed
  • 4 Yeung MJ, Pasieka JL. Well-differentiated thyroid carcinomas: management of the central lymph node compartment and emerging biochemical markers. J Oncol 2011; 2011: 705305
    PubMedGoogle Scholar
  • 5 Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949-954
    CrossrefPubMedGoogle Scholar
  • 6 Caronia LM, Phay JE, Shah MH. Role of BRAF in thyroid oncogenesis. Clin Cancer Res 2011; 17: 7511-7517
    CrossrefPubMedGoogle Scholar
  • 7 Gomez Saez JM. Diagnostic and prognostic markers in differentiated thyroid cancer. Curr Genomics 2011; 12: 597-608
    CrossrefPubMedGoogle Scholar
  • 8 Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007; 28: 742-762
    CrossrefPubMedGoogle Scholar
  • 9 Bendlova B, Dvorakova S, Sykorova V et al. Nadory stitne zlazy – molekularne geneticke priciny a moznosti cilene lecby [Thyroid tumours – molecular genetics causes and targeted treatment possibilities]. Cas Lek Cesk 2012; 151: 123-127
    PubMedGoogle Scholar
  • 10 Sykorova V, Dvorakova S, Ryska A et al. BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic. J Endocrinol Invest 2010; 33: 318-324
    CrossrefPubMedGoogle Scholar
  • 11 Cantara S, Capezzone M, Marchisotta S et al. Impact of proto-oncogene mutation detection in cytological specimens from thyroid nodules improves the diagnostic accuracy of cytology. J Clin Endocrinol Metab 2010; 95: 1365-1369
    CrossrefPubMedGoogle Scholar
  • 12 Nucera C, Lawler J, Hodin R et al. The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?. Oncotarget 2010; 1: 751-756
    PubMedGoogle Scholar
  • 13 Lee JH, Lee ES, Kim YS. Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid – A meta-analysis. Cancer 2007; 110: 38-46
    Google Scholar
  • 14 Ito Y, Miyauchi A. Prognostic factors and therapeutic strategies for differentiated carcinomas of the thyroid. Endocr J 2009; 56: 177-192
    CrossrefPubMedGoogle Scholar
  • 15 Liu RT, Chen YJ, Chou FF et al. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf) 2005; 63: 461-466
    CrossrefPubMedGoogle Scholar
  • 16 Czarniecka A, Rusinek D, Stobiecka E et al. Occurrence of BRAF mutations in a Polish cohort of PTC patients – preliminary results. Endokrynol Pol 2010; 61: 462-466
    PubMedGoogle Scholar
  • 17 Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214
    Google Scholar
  • 18 Kim TH, Park YJ, Lim JA et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012; 118: 1764-1773
    CrossrefPubMedGoogle Scholar
  • 19 Rivera M, Ricarte-Filho J, Tuttle RM et al. Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension. Thyroid 2010; 20: 1085-1093
    CrossrefPubMedGoogle Scholar
  • 20 Xing M, Vasko V, Tallini G et al. BRAF T1796A transversion mutation in various thyroid neoplasms. J Clin Endocrinol Metab 2004; 89: 1365-1368
    CrossrefPubMedGoogle Scholar
  • 21 Zatelli MC, Trasforini G, Leoni S et al. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies. Eur J Endocrinol 2009; 161: 467-473
    CrossrefPubMedGoogle Scholar
  • 22 Abrosimov A, Saenko V, Rogounovitch T et al. Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status. Int J Cancer 2007; 120: 196-200
    CrossrefPubMedGoogle Scholar
  • 23 Durante C, Puxeddu E, Ferretti E et al. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 2007; 92: 2840-2843
    CrossrefPubMedGoogle Scholar
  • 24 Parisi F, Micsinai M, Strino F et al. Integrated analysis of tumor samples sheds light on tumor heterogeneity. Yale J Biol Med 2012; 85: 347-361
    PubMedGoogle Scholar
  • 25 Fugazzola L, Puxeddu E, Avenia N et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006; 13: 455-464
    CrossrefPubMedGoogle Scholar
  • 26 Mani C, Selvakumar N, Kumar V et al. Comparison of DNA sequencing, PCR-SSCP and PhaB assays with indirect sensitivity testing for detection of rifampicin resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2003; 7: 652-659
    PubMedGoogle Scholar
  • 27 Jiang W, Wang W, Fu F et al. A more sensitive platform for the detection of low-abundance BRAF(V600E) mutations. Mol Cell Biochem 2012; 366: 49-58
    CrossrefPubMedGoogle Scholar
  • 28 Kumagai A, Namba H, Akanov Z et al. Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer. Endocr J 2007; 54: 399-405
    CrossrefPubMedGoogle Scholar
  • 29 Namba H, Nakashima M, Hayashi T et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003; 88: 4393-4397
    CrossrefPubMedGoogle Scholar
  • 30 Dusek L, Muzik J, Kubasek M et al. Epidemiology of Malignant Tumours in the Czech Republic. , Version 7.0 [online], Masaryk University, http://www.svod.cz [viewed September 13, 2013]. 2005
    PubMedGoogle Scholar
  • 31 Curry JL, Torres-Cabala CA, Tetzlaff MT et al. Molecular platforms utilized to detect BRAF V600E mutation in melanoma. Semin Cutan Med Surg 2012; 31: 267-273
    CrossrefPubMedGoogle Scholar
  • 32 Lin XQ, Finkelstein SD, Zhu B et al. Molecular analysis of multifocal papillary thyroid carcinoma. J Mol Endocrinol 2008; 41: 195-203
    CrossrefPubMedGoogle Scholar
  • 33 Anderson S, Bloom KJ, Vallera DU et al. Multisite analytic performance studies of a real-time Polymerase chain reaction assay for the detection of BRAF V600E mutations in formalin-fixed, paraffin-embedded tissue specimens of malignant melanoma. Arch Pathol Lab Med 2012; 136: 1385-1391
    CrossrefPubMedGoogle Scholar
  • 34 Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol 2010; 321: 86-93
    CrossrefPubMedGoogle Scholar
  • 35 Gouveia C, Can NT, Bostrom A et al. Lack of association of BRAF mutation with negative prognostic indicators in papillary thyroid carcinoma: the University of California, San Francisco, experience. JAMA Otolaryngol Head Neck Surg 2013; [Epub ahead of print]
    PubMedGoogle Scholar
  • 36 Guerra A, Sapio MR, Marotta V et al. The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab 2012; 97: 517-524
    CrossrefPubMedGoogle Scholar
  • 37 Eloy C, Santos J, Soares P et al. The preeminence of growth pattern and invasiveness and the limited influence of BRAF and RAS mutations in the occurrence of papillary thyroid carcinoma lymph node metastases. Virchows Arch 2011; 459: 265-276
    CrossrefPubMedGoogle Scholar